These two stocks have moved in different directions this year, but that shouldn't mean much to long-term investors.

Anyone who got sick with COVID-19 during the summer wave in South Florida has some protection against a future infection, but ...

With $35 million in funding, Qnovia hopes its device will become the first new prescription nicotine replacement therapy in ...

Stocks looked set to extend gains on Friday after mostly finishing higher the previous day. The market is getting a lift from ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

NEW YORK — U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

With a focus on cancer and autoimmune conditions, UBS has launched its coverage of 13 small and mid-cap biotechs, noting that ...

Former U.S. Marine John Mark Dougan, whose "Chicago Chronicle" was taken offline earlier this year after being revealed as a ...

STAT's Readout LOUD podcast discusses Pfizer's woes, explains RFK Jr.'s 'MAHA' campaign, and mulls the latest about the Novo ...

U.S. health officials are recommending that people 50 and older get a shot against bacteria that can cause pneumonia and ...

It is suggested that the platforms could influence patients in favour of the pharma giants or lead to inappropriate ...